The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.

TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...

Merck. Moderna & Merck announce 5-year data for intismeran autogene in combination with KEYTRUDA (pembrolizumab) demonstrated sustained improvement in recurrence-free survival in patients with ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

"We may be witnessing the beginning of an entirely new way of treating cancer," expert say ...

Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected ...

Generic and biosimilar cancer drugs are up to 93% cheaper under revised NPPA prices, but MRPs of 65 high-cost, single-source medicines remain unchanged. The new rates kick in on 9 November.

An Australian-led trial has produced a world-first cancer vaccine that could change the odds for thousands. The results are ...

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Merck’s Keytruda plus Padcev receives European Commission approval to treat adults with resectable muscle-invasive bladder cancer: Rahway, New Jersey Friday, October 23, 2026, 1 ...

TuHURA Biosciences (NASDAQ:HURA) presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in ...

A personalised mRNA cancer vaccine jointly developed by Moderna Inc (NASDAQ:MRNA, XETRA:0QF) and MSD (Unlisted (UK):MSD) has reduced the risk of melanoma recurrence or death by 42% in a landmark Phase ...